Research Project
Project Title: |
Phase 3, randomized, blinded, multicentre, placebo-controlled study to evaluate the efficacy and safety of Inebilizumab in IgG4-related disease (MITIGATE). |
Project Type: |
Clinical Trial, Enrolment ongoing |
Disease group(s): |
Immune glomerulopathies |
Project Summary: |
Phase 3, randomized, blinded, multicentre, placebo-controlled study to evaluate the efficacy and safety of Inebilizumab in IgG4-related disease (MITIGATE). |
Lead principal investigator(s): |
Dario Roccatello, Turin |
Project Period: |
10/2020 - 12/2060 |
Sponsors: |
Industry |
ClinicalTrials.gov: |
NCT04540497 |
« Back to research page